Immuno-Oncology | Specialty

Metastatic NSCLC: A Look at the IMpower150 Trial

June 28th 2018

Pembrolizumab: Monotherapy Versus Combination Therapy

June 28th 2018

Pembrolizumab and Chemotherapy in Advanced NSCLC

June 28th 2018

Implications for Pembrolizumab in NSCLC

June 28th 2018

Dr. Pal Discusses the Role of PD-L1 in Metastatic RCC

June 27th 2018

Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma.

Findings Set Stage for Expanded Immunotherapy Role in Bladder Cancer

June 26th 2018

Researchers now are turning their attention toward earlier disease settings involving patients who are refractory to standard therapies in nonmuscle-invasive bladder cancer or who are poor candidates for surgery in muscle-invasive bladder cancer.

Atezolizumab Combo Improves Survival in Frontline SCLC

June 25th 2018

Combining frontline atezolizumab with chemotherapy improved overall survival and progression-free survival compared with chemotherapy alone in patients with extensive-stage small cell lung cancer.

FDA Accepts Application for Adjuvant Pembrolizumab for Stage III Melanoma

June 25th 2018

The FDA has accepted a supplemental biologics license application for the use of pembrolizumab as an adjuvant treatment for patients with resected, high-risk stage III melanoma.

Dr. Galsky Discusses the Rationale for the IMvigor130 Study in Bladder Cancer

June 23rd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses the rationale for the IMvigor130 study in metastatic bladder cancer.

Dr. Glaspy on Immunotherapy in Endometrial Cancer

June 23rd 2018

John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles School of Medicine, discusses immunogenicity in endometrial cancer.

FDA Accepts Application for Frontline Nivolumab/Ipilimumab in TMB-High NSCLC

June 22nd 2018

The FDA has accepted a supplemental biologics license application for the combination of nivolumab plus ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.

FDA Adds PD-L1 Expression to Frontline Pembrolizumab, Atezolizumab Urothelial Carcinoma Labels

June 21st 2018

The FDA has incorporated PD-L1 status into the labels for pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma.

Agarwal Addresses Sequencing Challenges in Kidney Cancer

June 19th 2018

Neeraj Agarwal, MD, discusses his preferred sequencing strategies for treating patients with kidney cancer, and ongoing immunotherapy research in the field.

Dr. Zibelman on Managing Immune-Related Adverse Events

June 16th 2018

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, advisory committee of the Association of Community Cancer Centers, discusses the management of immune-related adverse events (irAEs).

Dr. Borghaei Discusses the Results of CheckMate-227 in NSCLC

June 14th 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the CheckMate-227 trial in non–small cell lung cancer.

Dr. Gupta on Phase Ib/II Trial of Pembrolizumab With Bevacizumab in RCC

June 14th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the phase Ib/II studies of pembrolizumab with bevacizumab for the treatment of patients with metastatic renal cell carcinoma.

Expert Says Paradigm Shift Imminent in SCLC

June 7th 2018

Anne Chiang, MD, PhD, discusses recent developments with immunotherapy and the overall outlook for the treatment landscape of small cell lung cancer.

Nivolumab Plus Low-Dose Ipilimumab Shows Durable Responses for PD-L1-Negative, TMB-High NSCLC

June 6th 2018

The combination of nivolumab and low-dose ipilimumab reduced the risk of progression or death by 52% compared with standard platinum doublet chemotherapy for patients with metastatic PD-L1–negative, tumor mutation burden-high non–small cell lung cancer.

Frontline Atezolizumab Regimen Improves Survival for NSCLC

June 5th 2018

The combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel educed the risk of death by 22% compared with bevacizumab and chemotherapy in patients with advanced wild-type non-squamous non–small cell lung cancer.

Dr. Jotte on the IMpower131 Findings in Squamous NSCLC

June 4th 2018

Robert M. Jotte, MD, PhD, medical director and co-chair, USON Thoracic Committee, Rocky Mountain Cancer Centers, discusses the phase III findings of the IMpower131 trial, which looked at the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) in patients with advanced squamous non